Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis

Blood

Volumn 126, Issue 2, 2015, Pages 167-175

  Lee, Stanley C W ^a,b   Miller, Sarah ^a   Hyland, Craig ^a   Kauppi, Maria ^a,b   Lebois, Marion ^a   Rago, Ladina Di ^a   Metcalf, Donald ^a,b   Kinkel, Sarah A ^a,b   Josefsson, Emma C ^a,b   Blewitt, Marnie E ^a,b   Majewski, Ian J ^a,b   Alexander, Warren S ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN; SUPPRESSOR OF ZESTE 12; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; SUZ12 PROTEIN, MOUSE;

ADULT; ALLELE; ANIMAL CELL; ARTICLE; BLOOD CELL; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; COLONY FORMING UNIT GM; CONTROLLED STUDY; EMBRYO; EOSINOPHIL; EXON; FETUS LIVER; GENE EXPRESSION; GENOTYPE; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; IMMUNOBLOTTING; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTOPOIESIS; LYMPHOID PROGENITOR CELL; LYMPHOPOIESIS; MEGAKARYOCYTE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MONOCYTE; MOUSE; MYELOID PROGENITOR CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN FUNCTION; SPLEEN; T LYMPHOCYTE; THROMBOCYTOPENIA; THYMUS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; FETUS; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; FETUS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; LYMPHOPOIESIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84937775807     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-615898     Document Type: Article

References (50)

1. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell. 2012;10(2):120-136.
2. Majewski IJ, Blewitt ME, de Graaf CA, et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 2008; 6(4):e93.
3. Adams GB. Deconstructing the hematopoietic stem cell niche: revealing the therapeutic potential. Regen Med. 2008;3(4):523-530.
4. Butler JS, Dent SY. The role of chromatin modifiers in normal and malignant hematopoiesis. Blood. 2013;121(16):3076-3084.
5. Paralkar VR, Weiss MJ. Long noncoding RNAs in biology and hematopoiesis. Blood. 2013;121(24): 4842-4846.
6. Wilkinson AC, Göttgens B. Transcriptional regulation of haematopoietic stem cells. Adv Exp Med Biol. 2013;786:187-212.
7. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3): 299-313.
8. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343-349.
9. Faust C, Lawson KA, Schork NJ, Thiel B, Magnuson T. The Polycomb-group gene eed is required for normal morphogenetic movements during gastrulation in the mouse embryo. Development. 1998;125(22):4495-4506.
10. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol. 2001;21(13): 4330-4336.
11. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004;23(20): 4061-4071.
12. Aoki R, Chiba T, Miyagi S, et al. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/ progenitor cells. J Hepatol. 2010;52(6):854-863.
13. Chamberlain SJ, Yee D, Magnuson T. Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells. 2008;26(6):1496-1505.
14. Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009;136(6):1122-1135.
15. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol. 2007;27(10):3769-3779.
16. Pereira JD, Sansom SN, Smith J, Dobenecker MW, Tarakhovsky A, Livesey FJ. Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci USA. 2010;107(36):15957-15962.
17. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008;32(4):491-502.
18. Mochizuki-Kashio M, Mishima Y, Miyagi S, et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood. 2011;118(25):6553-6561.
19. Su IH, Basavaraj A, Krutchinsky AN, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol. 2003;4(2):124-131.
20. Xie H, Xu J, Hsu JH, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell. 2014;14(1):68-80.
21. Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677-692.
22. Zhang Y, Kinkel S, Maksimovic J, et al. The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood. 2014;124(5): 737-749.
23. Su IH, Dobenecker MW, Dickinson E, et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell. 2005; 121(3):425-436.
24. Hidalgo I, Herrera-Merchan A, Ligos JM, et al. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell. 2012;11(5):649-662.
25. Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun. 2012;3:623.
26. Kamminga LM, Bystrykh LV, de Boer A, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2006; 107(5):2170-2179.
27. Majewski IJ, Ritchie ME, Phipson B, et al. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood. 2010;116(5):731-739.
28. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 1999;13(20):2691-2703.
29. Richie ER, Schumacher A, Angel JM, Holloway M, Rinchik EM, Magnuson T. The Polycombgroup gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene. 2002;21(2):299-306.
30. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
31. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2): 181-185.
32. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
33. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18(2):298-301.
34. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 2012;119(5):1208-1213.
35. Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012; 26(7):651-656.
36. Takeuchi T, Nomura T, Tsujita M, et al. Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting. Biochem Biophys Res Commun. 2002;293(3):953-957.
37. Schwenk F, Baron U, Rajewsky K. A cretransgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995; 23(24):5080-5081.
38. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8(4):265-277.
39. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
40. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol.2003;23(24): 9003-9013.
41. Anastassiadis K, Glaser S, Kranz A, Berhardt K, Stewart AF. A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2. Methods Enzymol. 2010;477:109-123.
42. Croker BA, Metcalf D, Robb L, et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity. 2004;20(2):153-165.
43. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125(2):301-313.
44. Lee SC, Phipson B, Hyland CD, et al. Polycomb repressive complex 2 (PRC2) suppresses Em-myc lymphoma. Blood. 2013;122(15): 2654-2663.
45. Ezhkova E, Lien WH, Stokes N, Pasolli HA, Silva JM, Fuchs E. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 2011;25(5):485-498.
46. Xu J, Shao Z, Li D, et al. Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. Mol Cell. 2015;57(2):304-316.
47. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338(6113):1465-1469.
48. Neff T, Sinha AU, Kluk MJ, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci USA. 2012;109(13): 5028-5033.
49. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
50. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA. 2012; 109(52):21360-21365.